Tag Archives: Reimbursement

Incorporation of new health technologies and pricing in Brasil’s health system

20 Sep
Brazil HTA 1

C&C co-hosted with #Abrale the Masterclass at TJCC 2019 where we covered the incorporation of new health technologies and pricing in Brasil’s health system. We had speakers from CONITEC, patient organizations (rare diseases and multiple sclerosis), independent legal and communication experts, and TechValue. Among the issues covered was the fair pricing of new health technologies […]

Value-Based Pricing of New Technologies

13 Aug
price and value balance sign

Health insurance companies and governments use strong financial and administrative barriers to manage the utilization of new technologies. Cost-sharing (co-insurance or co-payments), prior authorization, clinical panel reviews, therapeutic reference pricing, and new technology appraisals are designed to manage the incremental uptake of new technologies. These technologies, for example, PCSK-9 inhibitors and enzyme replacement therapies, are […]

Is Real-World Evidence all it’s trumped-up to be?

10 Apr
multiplechro

There’s so much discussion around Big Data and Real-World Evidence (RWE) in improving access to medicines. RWE is clinical data collected after the publication of clinical trials used for marketing authorization. Sources may include health insurance claims databases, patient registries, hospital patient records, among others. Clinical trials are by design the gold standard for new […]

WHO’s serious reservations on Value-Based Pricing: Conflicts and Nuances

08 Jun
WHO Fair Pricing Forum Carapinha & Company

On May 10 and 11, the WHO Fair Pricing Forum met to discuss improvements to medicine pricing practices and pricing approaches that balance public health needs and incentives for pharmaceutical research and development. The Forum was established to facilitate the exchange of insights on fairer medicine pricing systems, identification of research gaps to support improvements, […]

En garde QALY! Is your end nigh?

05 Apr
qalys

The Spanish Ministry of Health recently rejected the use of QALYs in cost-effectiveness analyses. At issue is the subjective nature of the parameters used to develop the QALY. The Quality-Adjusted Life-Years (QALY) is a product of the change in utilities associated with a treatment multiplied by the time of treatment exposure. The QALYs gained combined […]

ISPOR South Africa: Panel Presentation

18 Sep

This presentation provides highlights of a recent paper published by Dr. João  Carapinha on a comparative review of the Pharmacoeconomic Guidelines in South Africa with twelve other countries. An abstract and more background information on the paper is also available here.  

Webinar “creating value with accessed-based marketing”: themes and reflecting on a way-forward

26 May

Carapinha & Consultants partnered with eyeforpharma to bring a webinar on creating value with accessed-based marketing. The webinar was structured around 3 core questions that eyeforpharma’s Paul Simms used to facilitate the discussion. Question 1 The first question, “In order for the industry to move forward, pharma has to prioritize” generated interesting results. 69% of respondents […]

Webinar: “Remove barriers to entry by embracing an access-based approach to marketing”

19 May
eyeforpharmabanner

We’ve joined eyeforpharma as their Strategic Partner to bring you a free webinar: “Remove barriers to entry by embracing an access-based approach to marketing” on Tuesday 26th May 2:30-3:30 pm SAST. Pharma companies in South Africa have products with compelling economic value propositions, however reimbursement constraints have limited the up-take and patient access to new therapies. But how do we […]

Carapinha Logo